A Promising Pipeline for COPD

News
Video

Mannino, Anzueto and Christenson conclude the panel with thoughts on developing biologics for COPD, and increased interest in the field after ensifentrine and dupilumab.

In the final segment of HCPLive Special Report – RX Reviews on chronic obstructive pulmonary disease (COPD) drug development, panel moderator David Mannino, MD, chief medical officer of the COPD Foundation and professor at the University of Kentucky, discussed the short-term future of COPD drug research and development with panelists Antonio Anzueto, MD, professor of medicine and section chief of pulmonary at South Texas Veterans Healthcare System, and Stephanie Christenson, MD, associate professor of medicine at the University of California, San Francisco.

As the trio concluded discussion around the late-stage development and promising US Food and Drug Administration (FDA) applications for dupilumab (Dupixent) and ensifentrine (Ohtuvayre), they considered matters including a rekindled interest in novel drug development to treat the heterogenous, multifactorial and globally burdensome lower respiratory disease COPD. The advancement of dupilumab and ensifentrine to real-world COPD use aligns with similar targeted therapy progressions for other chronic respiratory diseases including cystic fibrosis, Mannino said.

Anzueto and Christenson additionally noted that at least another half-dozen biologic therapies are progressing in the COPD pipeline, with late-stage clinical data anticipated in the next 2-3 years. This may just be the beginning of a COPD therapy renaissance.

Check out the entire 3-part Special Report series, ‘COPD: New Therapy Breakthroughs’:

Part 1: What the Ensifentrine FDA Approval Means for COPD

Part 2: Projecting Dupilumab's Fit in COPD

Part 3: A Promising Pipeline for COPD

Our Moderator:

David M. Mannino, MD, Chief Medical Officer and Co-Founder of the COPD Foundation, and Professor of Internal Medicine, Pulmonary, Critical Care and Sleep Medicine at the University of Kentucky.

Our Panelists:

Antonio Anzueto, MD, Professor of Medicine and Section Chief of Pulmonary at South Texas Veterans Healthcare System.

Stephanie Christenson, MD, Associate Professor of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine at University of California, San Francisco.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
4 KOLs are featured in this series
4 KOLs are featured in this series
Video 4 - Featuring 3 KOLs in, "Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease "
Video 3 - Featuring 3 KOLs in, "How important is transmural healing as a treatment target in UC and CD?   Where does intestinal ultrasound fit in CD management?  "
4 KOLs are featured in this series
4 KOLs are featured in this series
A panel of 3 experts on COPD
© 2024 MJH Life Sciences

All rights reserved.